Work

A second chance for avatrombopag in chemotherapy‐induced thrombocytopenia

Year: 2024

Type: article

Abstract: Chemotherapy-induced thrombocytopenia (CIT) remains a common complication of cancer therapy with no approved available treatments in most of the world. Although a prior clinical trial of avatrombopag for CIT did not meet its primary end-point, a report from Galamaga and colleagues raises prospects for a second chance for avatrombopag in CIT, highlighting the differences between nadir and persistent CIT and the importance of patient selection in CIT treatment. Commentary on: Galamaga et al. Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: a case series. Br J Haematol 2025; 206:272-278.

Source: British Journal of Haematology

DOI: 10.1111/bjh.19861

Authors: Hanny Al‐Samkari, Donald C. Moore

Institutions: Harvard University, Massachusetts General Hospital, Levine Cancer Institute

Language: English

Topic: Platelet Disorders and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Heart, Lung, and Blood Institute